Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax's updated COVID-19 vaccine is now available at a wide range of retailers, including Costco, CVS Pharmacy, Giant, Publix, Rite Aid, Stop & Shop and Topco Novavax's vaccine is the only protein-based non-mRNA COVID-19 vaccine option in the U.S. Novavax's vaccine finder is available at us.novavaxcovidvaccine.com GAITHERSBURG, Md. , Oct. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has finalized agreements with major pharmacy retailers and prominent Group Purchasing Organizations (GPO) in the U.S. to provide the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) to prevent COVID-19 in individuals aged 12 and older this vaccination season.

Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.

Novavax stock initially jumped after the FDA signed off on its updated Covid shot. Is NVAX stock a buy right now?

Is Novavax Stock A Buy After The FDA — Finally — Signed Off On Its Updated Covid Shot?

Novavax missed out on a big opportunity for vaccine revenue -- but a new opportunity could be just ahead. Still, some uncertainty remains regarding the company's ability to turn things around and carve out market share.

The Fall Vaccination Season Is Here. Is Novavax a Buy?

GAITHERSBURG, Md. , Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023, October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

BioNTech SE

Moderna

Pfizer

Vaccine stocks delivered multibagger returns earlier in the pandemic. Their performance has suffered in recent times as some investors worry about revenue in a post-pandemic world.

The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.

Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio

Partnership with HealthyWomen and actor, mother and business owner Nicole Ari Parker encourages people to get informed about the importance of COVID vaccination and vaccine options  The Choose to Protect survey, conducted by The Harris Poll, found 85% of U.S. adults aged 45+ agree it is important to have a range of COVID vaccine options for themselves and their family1 Only two in five survey respondents say they are highly knowledgeable about the science behind different types of COVID vaccines1 GAITHERSBURG, Md. , Oct. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it has joined forces with HealthyWomen and actor, mother and business owner Nicole Ari Parker to launch Choose to Protect™, a campaign to educate the public about the importance of COVID vaccination and the different types of COVID vaccines.

Novavax Launches Choose to Protect™ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall

NVAX's H2'23 estimates appear to be overly bullish, based on PFE's pessimistic commentary with only 24% of the US population likely to be vaccinated with COVID vaccines in 2023. As a result of the potentially reduced demand, we may see NVAX's FY2023 revenue guidance further lowered in the upcoming FQ3'23 earnings call, triggering further volatility in its stock prices. NVAX will not record a profitable 2023 as well, based on the lowered $1.4B revenue guidance and $1.35B operating expenses, with COGS and interest expenses not even factored in yet.

Novavax's COVID-19 Investment Thesis Is Old News

Vaccine maker Novavax Inc on Monday said it has shipped its updated COVID-19 shots to distributors after receiving the go-ahead from U.S. regulators.

Updated Novavax COVID-19 vaccine shipped to distributors, to be available this week

Axcella Health Inc

Mind Medicine MindMed

Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.

3 Pharma Stocks to Dump Before the Damage Is Done

Novavax's Covid shot is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans — but analysts aren't worried about that delay.

Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall

Novavax is about to join Moderna and Pfizer in the fall vaccine marketplace. The company just won a nod from the FDA for its updated coronavirus vaccine shot, at a time when market demand is surpassing supply.

This Could be Novavax's Big Opportunity

Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.

Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab

Novavax (NASDAQ: NVAX ) stock rose 8% on Oct. 3 after the Food and Drug Administration (FDA) approved its updated Covid-19 vaccine. But short sellers now hold 54% of the float.

Short Sellers Are Betting Against Novavax (NVAX) Stock

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Novavax (NVAX) Soars 8.2%: Is Further Upside Left in the Stock?

The Food and Drug Administration signed off on Novavax's updated Covid booster late Tuesday, and NVAX stock surged just before the close.

Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna

This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid Find Novavax's vaccine at us.novavaxcovidvaccine.com or vaccines.gov GAITHERSBURG, Md. , Oct. 3, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Novavax Inc.'s NVAX, +11.57% new COVID shot got a green light from the U.S. Food and Drug Administration Tuesday.

Novavax updated COVID vaccine gets FDA approval

Shares were up more than 10% on the news, which came more than three weeks after vaccines from Moderna and Pfizer.

Novavax Stock Jumps After FDA Approves Updated Covid Vaccine

The U.S. Food and Drug Administration on Tuesday authorized an updated version of Novavax's protein-based COVID-19 vaccine for emergency use in individuals aged 12 years and older, the health regulator said.

US FDA authorizes Novavax's updated COVID shot

Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.

FDA approves updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.

C3.ai

Carvana

As a CNBC report recently pointed out, some publicly traded enterprises are standing out but for the wrong reasons. Feeling the pressure from the specter of an extended period of heightened borrowing costs, hedge funds have placed some sizable bets against certain companies.

NVAX, AI, CVNA: The 3 Most Shorted Stocks This Month

ProKidney

Stock market investors are regularly monitoring highly shorted stocks, as the potential for an abrupt surge looms large.

Short squeeze alert for September 27th: 2 stocks that could skyrocket

Bionano Genomics

Nano-X Imaging

Biotech companies can offer some of the most explosive returns for an investor. Small-cap biotech companies are known to shoot up 100% overnight and also to dump 50% in an instant as well.

Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is Done

Novavax, Inc. stock has been facing a downward spiral, but there may be a short-term trading opportunity if FDA approval for its COVID-19 vaccine is positive. The high level of short interest in Novavax makes a short squeeze a possibility. Novavax's fundamental prospects beyond COVID-19, such as its NanoFlu influenza vaccine and R21/Matrix-M malaria vaccine, raise questions about its long-term sustainability.

News for Novavax Stock (NVAX)